-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Obesity can significantly increase morbidity and mortality, so the FDA has now approved five anti-obesity drugs.
Phase 3 trials showed that these drugs significantly improved heart-brain metabolism in obese patients compared to placebos, including significant weight loss.
researchers systematically retrieved a one-year randomized controlled trial (RCTs) using the five drugs included in the PubMed, Embase, The Cochrane Library, and The ClinicalTrials.gov database as of September 30, 2019, which explicitly reported the efficacy of the drug VS placebo.
, we conducted a meta-analysis that focused on the effects of these anti-obesity drugs on weight loss.
, the researchers reviewed the effects of these drugs on other heart-brain metabolic parameters, including major adverse events.
,,(N = 10435;? -3.07 Kg,95% CI,-3.76-2.37)、(N = 2985;? -9.77 Kg;95% CI,-11.73-7.81)、(N = 16856;? -3. 08 Kg;95% CI,-3.49-2.66)、(N = 3239;? -4.39 Kg;95% CI,-5.05-3.72)(N = 4978;? -5.25 Kg;95% CI,-6.17-4.32)(P <0.00001)。
.